In this discussion recorded at AMP 2024, CLI Global Society European Chapter Chairman Jos van den Berg, MD, and Vice-Chairman Thomas Zeller, MD, discuss the work that the Chapter has been doing to improve the lives of patients with critical limb ischemia.

In this video from AMP 2024, Dr van den Berg discusses the current state of critical limb ischemia in Europe. 

Endovascular treatment of critical limb ischemia has been shown to be effective in preventing amputation and is oftentimes the treatment modality of first choice.

Since there was a striking paucity of high-level comparative effectiveness evidence on the optimal treatment of patients with CLTI so far, both these landmark trials were awaited with great interest. However, study outcomes are conflicting and therefore worthy of intensive review and in-depth analysis for all medical professions confronted with such patients.

Barry Katzen interviews 10 experts on CLTI who each bring their varied specialties, experiences, and opinions to help us understand the BEST-CLI trial results. Study design analysis, generalizability, and real-world application are some of the topics discussed.

The initial results of the long-awaited BEST-CLI (Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia) trial were recently published in the New England Journal of Medicine. There is a lack of prospective, randomized data to guide treatment of peripheral arterial disease, and this landmark trial is worthy of review and analysis by any practitioner treating CLTI.

The objectives of this trial were to evaluate the safety and performance of the temporary stent in treating infrapopliteal arterial disease.

We performed a meta-analysis of randomized controlled trials investigating the clinical outcomes of patients undergoing percutaneous revascularization with DCB vs percutaneous transluminal angioplasty (PTA) of infrapopliteal arteries.